You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 7,393,639


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,393,639
Title:Methods for identifying genes and promoters of interest using the Impala transposon
Abstract: The invention concerns a new tool for efficient mutagenesis enabling the generation of a collection of mutants in fungi by random insertion of a characterised Fusarium oxysporum Impala transposon in the genome of said fungi. The invention also concerns the resulting mutants.
Inventor(s): Grosjean-Cournoyer; Marie-Claire (Caluire, FR), Villalba; Francois (Lyons, FR), Lebrun; Marc-Henri (Lyons, FR), Daboussi; Marie-Josee (Bures-sur-Yvette, FR)
Assignee: Bayer CropScience S.A. (Lyons, FR)
Application Number:10/614,923
Patent Claims:1. A method for identifying a gene associated with a detectable phenotype in a fungus, comprising: (a) transforming the fungus with a polynucleotide comprising a marker gene which would otherwise be transcriptionally active in the fungus but which has been inactivated by the insertion of a defective Impala transposon, said marker gene comprising, in the direction of transcription, a promoter regulatory sequence of the niaD gene from Aspergillus nidulans which is more than 0.4 kb long and which is functionally linked to the coding sequence of said marker gene; (b) mobilizing the defective Impala transposon using a transposase, the expression of which is controlled, under conditions which allow the excision of the Impala transposon, and further controlling expression of the transposase so as to permit reinsertion and stabilization of the Impala transposon in the genome of the fungus; (c) selecting at least one insertion mutant with said detectable phenotype; and (d) isolating the gene into which, or close to which, the Impala transposon has inserted in the insertion mutant selected in (c).

2. The method of claim 1, wherein the marker gene encodes an enzyme that is active in the fungus.

3. The method of claim 2, wherein the marker gene encodes a nitrate reductase or a nitrilase.

4. The method of claim 3, wherein the marker gene is a nitrate reductase gene from Aspergillus nidulans.

5. The method of claim 1, 2, 3, or 4, wherein Impala transposon is integrated into the promoter regulatory sequence.

6. The method of claim 5, wherein the Impala transposon carries an additional marker gene.

7. A method for identifying a gene associated with a detectable phenotype of interest in Magnaporthe grisca, comprising: (a) transforming Magnaporthe grisea fungi which lack the detectable phenotype of interest with a polynucleotide comprising a selectable marker gene, the coding sequence of which is functionally linked to a promoter regulatory sequence which is functional in Magnaporthe grisea, wherein an inserted Impala transposon suppresses expression of the marker gene, to produce transformants; (b) providing conditions which allow the transposition of the Impala transposon in the transformants; (c) screening the transformants for the expression of the marker gene in order to select insertion mutants resulting from the transposition and re-insertion of the Impala transposon; (d) selecting at least one insertion mutant with said detectable phenotype of interest; and (e) isolating the gene into which, or close to which, the Impala transposon has inserted in the insertion mutant selected in (d).

8. The method of claim 7, wherein the conditions which allow transpositions are provided include introducing a transposase.

9. A method for identifying a gene associated with a detectable phenotype of interest in a fungus, comprising: (a) transforming fungi which lack the detectable phenotype of interest with a polynucleotide comprising a selectable marker gene, the coding sequence of which is functionally linked to a promoter regulatory sequence which is functional in Magnaporthe grisca, wherein an inserted Impala transposon suppresses expression of the marker gene, to produce transformants; (b) providing a transposase to allow the transposition of the Impala transposon in the transformants; (c) screening the transformants for the expression of the marker gene in order to select insertion mutants resulting from the transposition and re-insertion of the Impala transposon; (d) selecting at least one insertion mutant with said detectable phenotype of interest; and (e) isolating the gene into which, or close to which, the Impala transposon has inserted in the insertion mutant selected in (d); wherein the marker gene is selected from the group consisting of: (i) a reporter gene selected from the group consisting of glucuronidase and green fluorescent protein: (ii) a gene that confers tolerance to an antibiotic selected from the group consisting of hygromycin, phleomycin and sulfonylurea; and (iii) a gene that confers tolerance to a bialaphos herbicide.

10. The method of claim 9, wherein the marker gene is a reporter gene selected from the group consisting of glucuronidase and green fluorescent protein.

11. The method of claim 9, wherein the marker gene is a gene that confers tolerance to an antibiotic selected from the group consisting of hygromycin, phleomycin, and sulfonylurea.

12. The method of claim 9, wherein the marker gene is the gene that confers tolerance to the herbicide bialaphos.

13. The method of claim 9, wherein the Impala transposon is integrated into the promoter regulatory sequence.

14. The method of claim 9, wherein the Impala transposon is integrated into an intron of the marker gene.

15. A method for identifying a promoter of interest in a fungus, comprising: (a) transforming fungi with a polynucleotide comprising a first marker gene, said first marker gene comprising a promoter regulatory sequence which is functional in Magnaporthe grisca functionally linked to the coding sequence of said first marker gene and an Impala transposon comprising a second marker gene, wherein expression of said first marker gene is inactivated by the insertion of the Impala transposon and the second marker gene lacks an operably linked promoter sequence, to produce transformants; (b) providing conditions which allow the transposition of the Impala transposon in the transformants; (c) screening the transformants for the expression of the first marker select insertion mutants resulting from the transposition of the Impala element; (d) selecting at least one insertion mutant which expresses the second marker gene; and (e) isolating the promoter into which, or close to which, the Impala transposon has inserted in the insertion mutant selected in (d) to result in expression of the second marker gene.

Details for Patent 7,393,639

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2019-03-22
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2019-03-22
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2019-03-22
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.